Esbriet

July 20, 2017July 20, 2017

Esbriet, Ofev Safety Profiles in Routine Practice Similar to Clinical Trial Reports, Study Finds

Esbriet, News

Patients with idiopathic pulmonary fibrosis (IPF) prescribed Ofev (nintedanib) or Esbriet (pirfenidone) in real-world practice have shown similar tolerability and adverse event profiles as those reported in large-scale clinical ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain Only Effective IPF Therapies Though PRM-151 is Gaining Ground, Comparison Study Finds

Esbriet, News

Esbriet (pirfenidone) and Ofev (nintedanib) remain the most reliably effective treatments for idiopathic pulmonary fibrosis (IPF), according to a study that used a time-course model to compare the effectiveness ... Read more

June 30, 2017June 30, 2017

Measures of IPF Therapy Effectiveness Should Include Patients’ Views of Success, Researchers Argue

Esbriet, News

Clinical trials of idiopathic pulmonary fibrosis (IPF) therapies should include measures that reflect patients’ views of the success of treatments, Columbia University Medical Center researchers contend. In particular, the trials should ... Read more

June 29, 2017June 29, 2017

European Commission Approves New Esbriet Tablet for IPF Treatment

Esbriet, News

The European Commission (EC) recently approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). According to Roche, Esbriet’s developer, the ... Read more

June 12, 2017June 12, 2017

Esbriet Stops Lung Fibrosis By Improving Functioning of Mitochondria, Study Shows

Esbriet, News

Esbriet (pirfenidone) stops the lung scarring in idiopathic pulmonary fibrosis (IPF) by improving the functioning of mitochondria, cell components that convert food to energy and regulate cell death, according to ... Read more

May 24, 2017May 25, 2017

Latest IPF Studies Also Support Esbriet for More Severe Lung Function Impairment

Esbriet, News

Treatment with Genentech‘s FDA-approved Esbriet (pirfenidone) has been shown in two independent studies to improve moderate to more severe lung function impairment in patients with idiopathic pulmonary fibrosis (IPF). The results ... Read more

May 24, 2017May 25, 2017

PBI-4050 Slows Pulmonary Fibrosis Patients’ Lung-function Decline, Phase 2 Trial Suggests

Esbriet, News

Prometic’s PBI-4050 leveled off idiopathic pulmonary fibrosis patients’ decline in lung function, indicating it is a promising treatment for the disease, according to a Phase 2 clinical trial. The ... Read more

May 18, 2017May 18, 2017

Genoa Secures $62 Million to Fund Phase 2 Trial of Inhaled Aerodyne for Idiopathic Pulmonary Fibrosis

Esbriet, News

Genoa Pharmaceuticals has completed a $62 million Series A financing round to pursue a Phase 2 clinical trial of Aerodone (inhaled pirfenidone) to treat idiopathic pulmonary fibrosis (IPF). The Seattle-based company also appointed Dr. ... Read more

May 11, 2017

7 Common Questions About Esbriet

Esbriet (pirfenidone) is an anti-fibrotic and anti-inflammatory drug used in the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Manufactured by Genentech and given FDA approval in 2014, the drug ... Read more

May 9, 2017May 9, 2017

Esbriet Lowers Risk of Respiratory Hospitalizations Among IPF Patients by Nearly Half, Study Finds

Esbriet, News

Besides its other benefits, Esbriet (pirfenidone) prevents respiratory-related hospitalizations in patients with idiopathic pulmonary fibrosis (IPF), according to a study examining data from more than 1,200 patients. Findings also ... Read more